文献速递泌尿生殖与妇科肿瘤放疗

治疗前多参数磁共振成像表现是局限性前列腺癌更准确的独立预后预测因素

Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-22

该前瞻性研究纳入185例接受近距离放疗和外照射放疗的局限性前列腺癌患者,中位随访46个月,评估基于多参数磁共振成像(mpMRI)的分期是否比传统临床变量更准确地独立预测结局。多因素竞争风险分析显示,mpMRI示前列腺外侵犯(EPE;mrT3a;HR 4.80;P=0.035)和精囊侵犯(SVI;mrT3b;HR 10.17;P=0.003)是生化失败的独立预测因素,穿刺活检阳性针数百分比是转移失败的唯一独立预测因素(HR 13.95;P=0.014)。

要点

  • mpMRI示EPE(mrT3a;HR 4.80;P=0.035)和SVI(mrT3b;HR 10.17;P=0.003)是生化失败的独立预测因素。
  • 穿刺活检阳性针数百分比是转移失败的唯一独立预测因素(HR 13.95;P=0.014)。
  • 传统临床变量(前列腺特异性抗原、Gleason评分、临床分期)均未预测生化失败或转移失败。

核心结论

  • 治疗前mpMRI表现可能是比传统临床变量更准确的独立结局预测因素。
  • mpMRI示EPE、SVI以及活检阳性针数百分比较高预测更差的预后。

研究设计与样本

  • 前瞻性研究,共185例接受近距离放疗和外照射放疗的局限性前列腺癌患者,其中高危123例、中危62例。
  • 主要终点为生化失败(最低点加2 ng/mL)和转移失败,采用描述性、单变量和多变量竞争风险分析。

主要发现

  • 中位年龄71岁(范围56-82);mpMRI分期mrT1-mrT2b占20.5%、mrT2c占37.3%、mrT3a占31%、mrT3b占11.2%。
  • Gleason评分6占22.2%、7占49.5%、8-10占28.2%;基线前列腺特异性抗原中位值11.7 ng/mL(范围2.9-153)。
  • 中位随访46个月(范围16-70),15例(8.1%)发生生化失败,9例(4.9%)发生远处转移。
  • 传统临床变量(前列腺特异性抗原、Gleason评分、临床分期)均未预测生化失败或转移失败。
  • 排除SVI患者后,mpMRI示EPE(mrT3a)是生化失败(HR 4.36;P=0.042)和转移失败(HR 5.76;P=0.010)的唯一独立预测因素。

关键数值与推荐

  • 多因素竞争风险分析:生化失败的独立预测因素为mpMRI示EPE(mrT3a;HR 4.80;P=0.035)和SVI(mrT3b;HR 10.17;P=0.003)。
  • 多因素竞争风险分析:转移失败的唯一独立预测因素为穿刺活检阳性针数百分比(HR 13.95;P=0.014)。
  • 排除SVI患者后:mpMRI示EPE(mrT3a)预测生化失败(HR 4.36;P=0.042)和转移失败(HR 5.76;P=0.010)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively determine whether multiparametric magnetic resonance imaging (mpMRI)-based staging is a more accurate independent predictor of outcome than traditional clinical variables for patients undergoing brachytherapy and external beam radiation therapy. METHODS AND MATERIALS: The primary endpoints were biochemical (nadir plus 2 ng/mL) and metastatic failure. Descriptive, univariate, and multivariate competing risks analyses were performed. The cumulative incidence rates were estimated to describe the cumulative risk of the events of interest. The magnitude of the increased risk was estimated using univariate and multivariate subdistribution hazard ratios. RESULTS: A total of 185 patients had undergone prospective treatment (123 with high risk and 62 with intermediate risk). The median age was 71 years (range 56-82). Of the patients, 20.5% had mpMRI-determined (mrT) stage mrT1-mrT2b, 37.3% had mrT2c, 31% had mrT3a, and 11.2% had mrT3b. The Gleason score was 6 in 22.2%, 7 in 49.5%, and 8 to 10 in 28.2%. The median baseline prostate-specific antigen was 11.7 ng/mL (range 2.9-153). After a median follow-up period of 46 months (range 16-70), 15 patients (8.1%) had developed biochemical failure and 9 (4.9%) had developed distant metastases. None of the traditional clinical variables (prostate-specific antigen, Gleason score, clinical stage) predicted for biochemical or metastatic failure. The multivariate competing risk analysis demonstrated that the 2 independent predictors of biochemical failure were the presence of extraprostatic extension (EPE; mrT3a; hazard ratio [HR] 4.80; P = .035) and presence of seminal vesicle invasion (SVI; mrT3b; HR 10.17; P = .003) on mpMRI. The only independent predictor of metastatic failure was the percentage of positive cores on prostate biopsy (HR 13.95; P = .014). After excluding patients with SVI, the only independent predictor of biochemical failure and metastatic failure was the presence of EPE (stage mrT3a) on mpMRI (HR 4.36; P = .042; and HR 5.76; P = .010, respectively). CONCLUSIONS: The pretreatment mpMRI findings might be more accurate independent predictors of the outcome than traditional clinical variables. In particular, the presence of EPE, SVI and a greater percentage of positive cores on biopsy predicted for a worse prognosis.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gomez-Iturriaga A, Casquero F, Pijoan JI, et al. Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29861199. doi:10.1016/j.ijrobp.2018.04.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。